Clinical Trial Update: A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating valemetostat tosylate (DS-3201b) in combination with atezolizumab and bevacizumab for hepatocellular carcinoma, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Valemetostat Tosylate (valemetostat tosylate)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING